Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1976 Jun;57(6):1540–1547. doi: 10.1172/JCI108424

Comparison of effects of 1 alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 in man.

A S Brickman, J W Coburn, G R Friedman, W H Okamura, S G Massry, A W Norman
PMCID: PMC436813  PMID: 932193

Abstract

The effects of short-term treatment with 1,25-dihydroxy-vitamin D3 [1,25(0H)2D3] or 1 alpha-hydroxy-vitamin D3 [1 alpha(OH)D3] on intestinal absorption of 47Ca were compared in 41 experiments in normals and 72 experiments in patients with chronic renal failure. 11 patients were studied a second time after treatment for 2-5 mo. Doses varied from 0.14 to 5.4 mug/day to establish dose-response relationships. Urinary calcium was monitored in normal subjects, nine of whom received a constant calcium intake on a metabolic unit. There was an increase in intestinal absorption of 47Ca and urinary calcium in normals receiving 1,25 (OH)2D3, 0.14 mug/day or greater, and 0.28 mug/day or greater augmented intestinal absorption of 47Ca in chronic renal failure. In contrast, 2.6 mug/day of 1 alpha (OH) D3 was required to increase intestinal absorption of 47Ca in both groups. The increase in urinary calcium to maximal levels was delayed during treatment with 1 alpha (OH) D3, 5-10 days vs. 2-5 days with 1,25 (OH)2D3. Moreover, half times for urinary calcium to decrease to pretreatment levels after stopping treatment were greater after 1 alpha-(OH) D3 (1.5-2.7 days) than 1,25(OH)2D3 (1.1-2.0 days). With long-term administration there was a progressive increase in intestinal absorption of 47Ca in the patients receiving 1 alpha (OH)D3; this was not observed with 1,25(OH)2D3. The pharmacologic differences between 1 alpha(OH) D3 and 1,25(OH)2D3 may be explained by the requirement for 25-hydroxylation of 1alpha(OH) D3 before biologic effects occur; at low doses (less than 1 mug/day), 1 alpha(OH) D3 competes with vitamin D3 for 25-hydroxylation. With prolonged treatment or larger doses (greater than 2 mug/day),, 1alpha(OH) D3 could accumulate and then be hydroxylated resulting in production of higher levels of 1,25(OH)2D3.

Full text

PDF
1540

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brickman A. S., Coburn J. W., Massry S. G., Norman A. W. 1,25 Dihydroxy-vitamin D3 in normal man and patients with renal failure. Ann Intern Med. 1974 Feb;80(2):161–168. doi: 10.7326/0003-4819-80-2-161. [DOI] [PubMed] [Google Scholar]
  2. Brickman A. S., Coburn J. W., Norman A. W. Action of 1,25-dihydroxycholecalciferol, a potent, kidney-produced metabolite of vitamin D, in uremic man. N Engl J Med. 1972 Nov 2;287(18):891–895. doi: 10.1056/NEJM197211022871801. [DOI] [PubMed] [Google Scholar]
  3. Catto G. R., MacLeod M., Pelc B., Kodicek E. I alpha-hydroxycholecalciferol: a treatment of renal bone disease. Br Med J. 1975 Jan 4;1(5948):12–14. doi: 10.1136/bmj.1.5948.12-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chalmers T. M., Hunter J. O., Davie M. W., Szaz K. F., Pelc B., Kodicek E. 1-Alpha-hydroxycholecalciferol as a substitute for the kidney hormone 1,25-dihydroxycholecalciferol in chronic renal failure. Lancet. 1973 Sep 29;2(7831):696–699. doi: 10.1016/s0140-6736(73)92536-1. [DOI] [PubMed] [Google Scholar]
  5. Chan J. C., Oldham S. B., Holick M. F., DeLuca H. F. 1-alpha-hydroxyvitamin D3 in chronic renal failure. A potent analogue of the kidney hormone, 1,25-dihydroxycholecalciferol. JAMA. 1975 Oct 6;234(1):47–52. [PubMed] [Google Scholar]
  6. Coburn J. W., Koppel M. H., Brickman A. S., Massry S. G. Study of intestinal absorption of calcium in patients with renal failure. Kidney Int. 1973 Apr;3(4):264–272. doi: 10.1038/ki.1973.40. [DOI] [PubMed] [Google Scholar]
  7. Cork D. J., Haussler M. R., Pitt M. J., Rizzardo E., Hesse R. H., Pechet M. M. 1Alpha-hydroxyvitamin D3: a synthetic sterol which is highly active in preventing rickets in the chick. Endocrinology. 1974 May;94(5):1337–1345. doi: 10.1210/endo-94-5-1337. [DOI] [PubMed] [Google Scholar]
  8. Fukushima M., Suzuki Y., Toira Y., Matsunaga I., Ochi K., Nagano H. Metabolism of 1alpha-hydroxyvitamin D3 to 1alpha, 25-dihydroxyvitamin D3 in perfused rat liver. Biochem Biophys Res Commun. 1975 Sep 16;66(2):632–638. doi: 10.1016/0006-291x(75)90556-2. [DOI] [PubMed] [Google Scholar]
  9. Haussler M. R., Zerwekh J. E., Hesse R. H., Rizzardo E., Pechet M. M. Biological activity of 1alpha-hydroxycholecalciferol, a synthetic analog of the hormonal form of vitamin D3. Proc Natl Acad Sci U S A. 1973 Aug;70(8):2248–2252. doi: 10.1073/pnas.70.8.2248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Henderson R. G., Russell R. G., Ledingham J. G., Smith R., Oliver D. O., Walton R. J., Small D. G., Preston C., Warner G. T. Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure. Lancet. 1974 Mar 9;1(7854):379–384. doi: 10.1016/s0140-6736(74)93149-3. [DOI] [PubMed] [Google Scholar]
  11. Holick M. F., Kasten-Schraufrogel P., Tavela T., DeLuca H. F. Biological activity of 1alpha-hydroxyvitamin D3 in the rat. Arch Biochem Biophys. 1975 Jan;166(1):63–66. doi: 10.1016/0003-9861(75)90365-3. [DOI] [PubMed] [Google Scholar]
  12. Holick M. F., Semmler E. J., Schnoes H. K., DeLuca H. F. 1 -Hydroxy derivative of vitamin D 3 : a highly potent analog of 1 ,25-dihydroxyvitamin D 3 . Science. 1973 Apr 15;180(4082):190–191. doi: 10.1126/science.180.4082.190. [DOI] [PubMed] [Google Scholar]
  13. Kopple J. D., Coburn J. W. Metabolic studies of low protein diets in uremia. II. Calcium, phosphorus and magnesium. Medicine (Baltimore) 1973 Nov;52(6):597–607. doi: 10.1097/00005792-197311000-00005. [DOI] [PubMed] [Google Scholar]
  14. Mitra M. N., Norman A. W., Okamura W. H. Studies on vitamin D and its analogs. I. Synthesis of 1alpha-hydroxycholest-5-ene. J Org Chem. 1974 Sep 20;39(19):2931–2933. doi: 10.1021/jo00933a027. [DOI] [PubMed] [Google Scholar]
  15. Narwid T. A., Blount J. F., Iacobelli J. A., Uskoković M. R. Vitamin D3 metabolites. 3. Synthesis and X-ray analysis of 1 alpha,25-dihydroxycholesterol. Helv Chim Acta. 1974 Apr 27;57(3):781–789. doi: 10.1002/hlca.19740570332. [DOI] [PubMed] [Google Scholar]
  16. Norman A. W., Midgett R. J., Myrtle J. F., Nowicki H. G. Studies on calciferol metabolism. I. Production of vitamin D metabolite 4B from 25-OH-cholecalciferol by kidney homogenates. Biochem Biophys Res Commun. 1971 Mar 19;42(6):1082–1087. doi: 10.1016/0006-291x(71)90015-5. [DOI] [PubMed] [Google Scholar]
  17. Peacock M., Gallagher J. C., Nordin B. E. Action of 1alpha-hydroxy vitamin D3 on calcium absorption and bone resorption in man. Lancet. 1974 Mar 9;1(7854):385–389. doi: 10.1016/s0140-6736(74)93150-x. [DOI] [PubMed] [Google Scholar]
  18. Procsal D. A., Okamura W. H., Norman A. W. Structural requirements for the interaction of 1 alpha, 25-(OH) 2- vitiamin D3 with its chick interestinal receptor system. J Biol Chem. 1975 Nov 10;250(21):8382–8388. [PubMed] [Google Scholar]
  19. Reynolds J. J., Holick M. F., DeLuca H. F. The effects of vitamin D analogues on bone resorption. Calcif Tissue Res. 1974;15(4):333–339. doi: 10.1007/BF02059069. [DOI] [PubMed] [Google Scholar]
  20. Tanaka Y., Frank H., DeLuca H. F. Biological activity of 1,25-dihydroxyvitamin D3 in the rat. Endocrinology. 1973 Feb;92(2):417–422. doi: 10.1210/endo-92-2-417. [DOI] [PubMed] [Google Scholar]
  21. Toffolon E. P., Pechet M. M., Isselbacher K. Demonstration of the rapid action of pure crystalline 1 alpha-hydroxy vitamin D3 and 1 alpha,25-dihydroxy vitamin D3 on intestinal calcium uptake. Proc Natl Acad Sci U S A. 1975 Jan;72(1):229–230. doi: 10.1073/pnas.72.1.229. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES